Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local radiation dose escalation with irinotecan-capecitabine total neoadjuvant therapy for organ preservation in low rectal cancer
ChiCTR2400080595Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan and capecitabine in rectal adenocarcinoma and rectal cancer, sponsored by Henan Cancer Hospital. Primary endpoint: Complete clinical response rate after treatment. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
irinotecancapecitabine
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on ChiCTR2400080595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080595.